Cargando…
DNA markers and nano-biosensing approaches for tuberculosis diagnosis
According to WHO 2018 report, 10 million people developed tuberculosis and 1.3 million died from it making it 1 of 10 deadliest diseases worldwide. Tuberculosis is caused by infection with the bacillus Mycobacterium tuberculosis (Mtb). WHO recommends using a specific diagnostic kit Xpert MTB/RIF dev...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303904/ http://dx.doi.org/10.1016/B978-0-12-819811-7.00013-8 |
_version_ | 1783548157156655104 |
---|---|
author | Rabti, Amal Raouafi, Amal Raouafi, Noureddine |
author_facet | Rabti, Amal Raouafi, Amal Raouafi, Noureddine |
author_sort | Rabti, Amal |
collection | PubMed |
description | According to WHO 2018 report, 10 million people developed tuberculosis and 1.3 million died from it making it 1 of 10 deadliest diseases worldwide. Tuberculosis is caused by infection with the bacillus Mycobacterium tuberculosis (Mtb). WHO recommends using a specific diagnostic kit Xpert MTB/RIF developed by Cepheid (California, United States). An alarming number of new cases (ca. 558,000) of rifampicin-resistant tuberculosis was diagnosticated in 2017. In recent years, new diagnosis tools targeting the Mtb DNA biomarkers have emerged using a plethora of nanomaterials capable of delivering new technological approaches for the rapid diagnostics of TB and rifampicin-resistant TB (RR-TB). In this chapter, we summarized the state-of-the-art of the current available DNA biomarkers and the potential applications for the development of new diagnosis nanotechnology-based devices. The latter use carbonaceous nanomaterials (graphene and carbon nanotubes), noble metals (silver and gold), semi-conducting (metal oxides, magnetic beads, and quantum dots) in order to reveal and/or to amplify the signal after the recognition of target DNA biomarker. The readout techniques such as colorimetry, fluorescence, surface plasmon resonance, and electrochemical methods were also reviewed. Future is bright for point-of-care diagnostics with a sample-in answer-out approach that hampers user-error through miniaturization of biochip technology to the nanoscale range, which will enable their use by nonspecialized personnel. |
format | Online Article Text |
id | pubmed-7303904 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
record_format | MEDLINE/PubMed |
spelling | pubmed-73039042020-06-19 DNA markers and nano-biosensing approaches for tuberculosis diagnosis Rabti, Amal Raouafi, Amal Raouafi, Noureddine Nanotechnology Based Approaches for Tuberculosis Treatment Article According to WHO 2018 report, 10 million people developed tuberculosis and 1.3 million died from it making it 1 of 10 deadliest diseases worldwide. Tuberculosis is caused by infection with the bacillus Mycobacterium tuberculosis (Mtb). WHO recommends using a specific diagnostic kit Xpert MTB/RIF developed by Cepheid (California, United States). An alarming number of new cases (ca. 558,000) of rifampicin-resistant tuberculosis was diagnosticated in 2017. In recent years, new diagnosis tools targeting the Mtb DNA biomarkers have emerged using a plethora of nanomaterials capable of delivering new technological approaches for the rapid diagnostics of TB and rifampicin-resistant TB (RR-TB). In this chapter, we summarized the state-of-the-art of the current available DNA biomarkers and the potential applications for the development of new diagnosis nanotechnology-based devices. The latter use carbonaceous nanomaterials (graphene and carbon nanotubes), noble metals (silver and gold), semi-conducting (metal oxides, magnetic beads, and quantum dots) in order to reveal and/or to amplify the signal after the recognition of target DNA biomarker. The readout techniques such as colorimetry, fluorescence, surface plasmon resonance, and electrochemical methods were also reviewed. Future is bright for point-of-care diagnostics with a sample-in answer-out approach that hampers user-error through miniaturization of biochip technology to the nanoscale range, which will enable their use by nonspecialized personnel. 2020 2020-06-19 /pmc/articles/PMC7303904/ http://dx.doi.org/10.1016/B978-0-12-819811-7.00013-8 Text en Copyright © 2020 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Rabti, Amal Raouafi, Amal Raouafi, Noureddine DNA markers and nano-biosensing approaches for tuberculosis diagnosis |
title | DNA markers and nano-biosensing approaches for tuberculosis diagnosis |
title_full | DNA markers and nano-biosensing approaches for tuberculosis diagnosis |
title_fullStr | DNA markers and nano-biosensing approaches for tuberculosis diagnosis |
title_full_unstemmed | DNA markers and nano-biosensing approaches for tuberculosis diagnosis |
title_short | DNA markers and nano-biosensing approaches for tuberculosis diagnosis |
title_sort | dna markers and nano-biosensing approaches for tuberculosis diagnosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303904/ http://dx.doi.org/10.1016/B978-0-12-819811-7.00013-8 |
work_keys_str_mv | AT rabtiamal dnamarkersandnanobiosensingapproachesfortuberculosisdiagnosis AT raouafiamal dnamarkersandnanobiosensingapproachesfortuberculosisdiagnosis AT raouafinoureddine dnamarkersandnanobiosensingapproachesfortuberculosisdiagnosis |